Friday, November 13, 2026

Wall Street Banks Deploy $130B Into Private Credit as Traditional Lending Shrinks

Goldman Sachs and Citigroup are shifting from traditional banking to alternative assets through $105B in private credit partnerships and strategic acquisitions. The pivot follows $25B in divestments including Citi's Russia exit and Goldman's Polish unit sale, reflecting margin pressure from low interest rates and tighter capital requirements facing global banks.

Wall Street Banks Deploy $130B Into Private Credit as Traditional Lending Shrinks
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Citigroup formed $105B in private credit partnerships with Apollo, BlackRock, and Carlyle between June 2024 and September 2025, while Goldman Sachs acquired two alternative investment firms in late 2025. The moves follow $25B in combined divestments as Wall Street banks retreat from traditional markets facing thin margins.

Goldman bought Industry Ventures in January 2026 and Innovator Capital Management in December 2025 after selling its Polish TFI unit to ING in November 2025. The bank raised dividends 12.5% in January 2026 and 33.3% in July 2025, with shares up 20.5% over six months.

Citigroup exited Russia in February 2026 by selling AO Citibank and offloaded equity stakes in Grupo Financiero Banamex the same month. The Russia withdrawal continues Western banks' retreat from the market since 2022. Banamex sales unwind Mexican retail operations Citi acquired in 2001.

Citi's partnerships include a $25B private credit platform with Apollo from September 2024, an $80B customized portfolio offering with BlackRock in September 2025, and asset-based lending with Carlyle from June 2025. BlackRock's deal provides access to Aladdin risk management technology for high-net-worth client portfolios.

JPMorgan consolidated U.S. consumer credit by acquiring Apple's credit card program in January 2026 and General Motors' program in September 2025. The takeovers signal concentration in retail banking as competitors pivot to alternatives.

Private credit partnerships let banks earn fees without holding loans on balance sheets, improving return on equity under Basel III capital requirements. Asset-based lending and structured products offer higher margins than traditional corporate loans in low-rate environments.

Goldman's acquisitions complement its $2.5T asset management division. Industry Ventures specializes in secondary venture investments, while Innovator focuses on defined outcome ETFs serving wealth management clients without branch network overhead.

The restructuring wave includes Citigroup's 20,000 job cuts announced in January 2024. Banks across North America and Europe face similar pressure to reduce costs while shifting capital to higher-margin alternative investments.


Sources:
1 Yahoo Finance, "FutureGen Industries Announces Open Market Investments" (March 23, 2026)
2 Globe Newswire, "ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Apollo Global Management, Inc. Investors to Secure C" (March 21, 2026)
3 Yahoo Finance, "Buying A Home Just Got Cheaper: FHFA Eases Insurance Rules, Cuts Costs For Borrowers" (March 22, 2026)
4 Yahoo Finance, "Mortgage Rates Hit Three-Month High as Iran War Rattles Spring Housing Market" (March 22, 2026)
5 Yahoo Finance, "Is JPMorgan Chase & Co. (JPM) A Good Stock To Buy Now?" (March 16, 2026)

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com